Spaya is developed by Iktos, a technology leader in AI applied to de novo drug design that has been active since 2016. Building on our experience in the field, we have identified synthetic accessibility and data-driven retrosynthetic analysis as a significant need of medicinal and synthetic chemists. Hence, we decided to embark on this journey and Spaya is the result of our endeavors.
